Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation.

dc.contributor.author

Austin, Stephanie L

dc.contributor.author

Chiou, Andrew

dc.contributor.author

Sun, Baodong

dc.contributor.author

Case, Laura E

dc.contributor.author

Govendrageloo, Kenny

dc.contributor.author

Hansen, Perrin

dc.contributor.author

Kishnani, Priya S

dc.coverage.spatial

United States

dc.date.accessioned

2017-07-24T14:33:14Z

dc.date.available

2017-07-24T14:33:14Z

dc.date.issued

2017-01

dc.description.abstract

OBJECTIVE: PRKAG2 syndrome, an autosomal dominant disorder, is characterized by severe infantile hypertrophic cardiomyopathy and heart rhythm disturbances to cases with a later presentation and a spectrum of manifestations including cardiac manifestations, myopathy and seizures. The cardiac features of PRKAG2 resemble the cardiac manifestations of Pompe disease. We present a patient who was initially diagnosed with Pompe disease and treated with alglucosidase-alfa enzyme replacement therapy (ERT); however, he was eventually diagnosed to carrying a PRKAG2 pathogenic gene mutation; he did not have Pompe disease instead he was a carrier for the common adult leaky splice site mutation in the GAA gene. CASE REPORT: At 2.5months, the patient had hypotonia/generalized muscle weakness, a diagnosis of non-classic infantile Pompe disease was made based on low acid alpha-glucosidase activity and the patient started on ERT at 11months. However, 1month later, the patient began to have seizures. As the patient's medical history was somewhat unusual for infantile Pompe disease, further evaluation was initiated and included a glycogen storage disease sequencing panel which showed that the patient had a pathogenic mutation in PRKAG2 which had been reported previously. ERT was discontinued and patient had a progression of motor deficits. ERT was reinitiated by the treating physician, and a clinical benefit was noted. CONCLUSION: This report outlines the benefits of ERT with alglucosidase alfa in a patient with PRKAG2 syndrome, the decline in his condition when the ERT infusions were discontinued, and the significant positive response when ERT was reinitiated.

dc.identifier

https://www.ncbi.nlm.nih.gov/pubmed/27692944

dc.identifier

S1096-7192(16)30283-9

dc.identifier.eissn

1096-7206

dc.identifier.uri

https://hdl.handle.net/10161/15079

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

Mol Genet Metab

dc.relation.isversionof

10.1016/j.ymgme.2016.09.006

dc.subject

AMP-activated protein kinase

dc.subject

Acid alpha-glucosidase

dc.subject

Cardiomyopathy

dc.subject

Glycogen storage disease

dc.subject

PRKAG2

dc.title

Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation.

dc.type

Journal article

duke.contributor.orcid

Sun, Baodong|0000-0002-2191-0025

duke.contributor.orcid

Case, Laura E|0000-0002-2941-2186

duke.contributor.orcid

Kishnani, Priya S|0000-0001-8251-909X

pubs.author-url

https://www.ncbi.nlm.nih.gov/pubmed/27692944

pubs.begin-page

96

pubs.end-page

100

pubs.issue

1-2

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Duke

pubs.organisational-group

Duke Clinical Research Institute

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Orthopaedics

pubs.organisational-group

Orthopaedics, Physical Therapy

pubs.organisational-group

Pediatrics

pubs.organisational-group

Pediatrics, Medical Genetics

pubs.organisational-group

School of Medicine

pubs.publication-status

Published

pubs.volume

120

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2016-Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a pt presenting with a PRKAG2 mutation.Oct 2016.pdf
Size:
426.6 KB
Format:
Adobe Portable Document Format